

28 Nov 2021 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: the prospects and plans for J&J's pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda; and Moderna's co-founder shares tips on innovation.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 12 November 2021, including: the prospects and plans for [\*Johnson & Johnson\*](#)'s pharma and oncology business; China looks more inward under new policies; an important US approval for [\*Takeda Pharmaceutical Co. Ltd.\*](#); and [\*Moderna, Inc.\*](#)'s co-founder shares tips on innovation.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [\*Apple Podcasts\*](#), [\*Google Podcasts\*](#), [\*SoundCloud\*](#), [\*TuneIn\*](#) and [\*Spotify Podcasts\*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[\*No Way To Go But Grow: J&J Outlines Plans To Become A \\$60bn Pharma In 2025\*](#)" - Scrip, 18 Nov, 2021.)

(Also see "[\*Janssen's Lebowitz On J&J's Oncology Expansion Plans Outside Of Hematology\*](#)" - Scrip, 18 Nov, 2021.)

(Also see "[\*Pharma Will Need To Embrace More Inward-Looking China\*](#)" - Scrip, 24 Nov, 2021.)

(Also see "[\*Takeda's Livtencity Approved For Refractory CMV Infection In Transplant Patients\*](#)" - Scrip, 25 Nov, 2021.)

(Also see "[\*Moderna Co-Founder Robert Langer's Tips For Innovation\*](#)" - Scrip, 22 Nov, 2021.)

[\*Click here to explore this interactive content online\*](#) ✎